Differential expression of the beta4 neuronal nicotinic receptor subunit affects tolerance development and nicotinic

Erin E Meyers1, Esteban C Loetz1, Michael J Marks2

  • 1Institute for Behavioral Genetics, 447 UCB, University of Colorado Boulder, Boulder, CO 80309, USA.

Insights

Mice lacking the β4 subunit of neuronal nicotinic acetylcholine receptors (nAChR) showed increased nicotine tolerance. This highlights the β4 subunit

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Neuronal nicotinic acetylcholine receptors (nAChRs) are implicated in nicotine addiction and tolerance.
  • The β4 subunit is a key component of certain nAChR subtypes, but its specific role in nicotine tolerance is not fully understood.

Purpose of the Study:

  • To investigate the role of the β4 subunit of nAChRs in the development of nicotine tolerance.
  • To examine the impact of chronic nicotine treatment on nAChR binding sites in mice with varying β4 subunit expression.

Main Methods:

  • Chronic nicotine administration via intravenous infusion to wild-type, heterozygous, and β4 subunit null mutant mice.
  • Assessment of dose-dependent nicotine tolerance.
  • Quantification of [(125)I]-epibatidine binding sites in various brain regions to measure nAChR levels.

Main Results:

  • Mice lacking the β4 subunit (β4(--)) exhibited significantly greater nicotine tolerance compared to wild-type (β4(++)) and heterozygous (β4(+-) ) mice.
  • Deletion of the β4 subunit led to decreased expression of 5IA-85380 resistant [(125)I]-epibatidine binding sites (primarily β4*-nAChR).
  • Cytisine-sensitive [(125)I]-epibatidine binding sites (primarily α4β2-nAChR) showed minimal changes in response to β4 subunit deletion or chronic nicotine treatment.

Conclusions:

  • The β4 subunit plays a critical role in regulating nicotine tolerance, with its absence exacerbating tolerance development.
  • Different nAChR subtypes containing the β4 subunit (β4*-nAChR) are differentially regulated and contribute uniquely to nicotine tolerance compared to α4β2-nAChR sites.

Related Concept Videos

Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
6.8K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.3K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72